Biosimilars in Dermatology: Current Situation (Part II);Biosimilares en dermatología. Situación actual (parte II)

Actas Dermo-Sifiliograficas

Volumn 106, Issue 7, 2015, Pages 550-554

  Puig, L ^a   Carretero, G ^b   Dauden E ^c   Ferrandiz C ^d   Marron S E ^e   Martorell, A ^f   Perez Suarez B ^g   Rodriguez Cerdeira, C ^h   Ruiz Villaverde, R ⁱ   Sanchez Carazo J L ^j   Velasco, M ^k  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD   (Spain)

^f HOSPITAL DE MANISES   (Spain)

^g HOSPITAL MORALES MESEGUER   (Spain)

^h Xerencia de Xestion Integrada de Vigo SERGAS   (Spain)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^j HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^k HOSPITAL ARNAU DE VILANOVA   (Spain)

more..

Author keywords

Adalimumab; Biologic; Biosimilar; Clinical trials; Etanercept; Infliximab; Interchangeability; Legislation; Psoriasis; Substitution

Indexed keywords

BIOSIMILAR AGENT; CT-P13; INFLIXIMAB; MONOCLONAL ANTIBODY;

ARTICLE; CLINICAL EVALUATION; DERMATOLOGY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HUMAN; PSORIASIS; PUBLIC HEALTH SERVICE; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG SUBSTITUTION; DRUG SURVEILLANCE PROGRAM; ECONOMICS; EUROPEAN UNION; LEGISLATION AND JURISPRUDENCE; SPAIN; SPONDYLITIS, ANKYLOSING; THERAPEUTIC EQUIVALENCE; DERMATOLOGIST; DRUG MARKETING; DRUG POTENCY; HEALTH CARE SYSTEM; SHORT SURVEY;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; BIOSIMILAR PHARMACEUTICALS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG SUBSTITUTION; EUROPEAN UNION; HUMANS; INFLIXIMAB; PHARMACOVIGILANCE; PSORIASIS; SPAIN; SPONDYLITIS, ANKYLOSING; THERAPEUTIC EQUIVALENCY;

EID: 85044287326     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/j.ad.2015.04.008     Document Type: Short Survey

References (18)

1. Inflectra Assessment report [consultado 25 Ene 2015]. Disponible en: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/002778/WC500151490.pdf
2. B.J. Scott, A.V. Klein, and J. Wang Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation J Clin Pharmacol 55 Suppl 3 2015 S123-32
3. H.C. Ebbers Biosimilars: In support of extrapolation of indications J Crohns Colitis 8 2014 431 435
4. B.G. Feagan, D. Choquette, S. Ghosh, D.D. Gladman, V. Ho, B. Meibohm, and et al. The challenge of indication extrapolation for infliximab biosimilars Biologicals 42 2014 177 183
5. G. Fiorino, G. Girolomoni, G. Lapadula, A. Orlando, S. Danese, and I. Olivieri SIR, SIDeMaST, and IG-IBD. The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper Autoimmun Rev 13 2014 751 755
6. J.E. Fonseca, J. Gonçalves, F. Araújo, I. Cordeiro, F. Teixeira, H. Canhão, and et al. Sociedade Portuguesa de Reumatologia. The Portuguese Society of Rheumatology position paper on the use of biosimilars Acta Reumatol Port 39 2014 60 71
7. L. Puig Biosimilars and reference biologics: Decisions on biosimilar interchangeability require the involvement of dermatologists Actas Dermosifiliogr 105 2014 435 437
8. M. Weise, P. Kurki, E. Wolff-Holz, M.C. Bielsky, and C.K. Schneider Biosimilars: The science of extrapolation Blood 124 2014 3191 3196
9. J. Miletich, G. Eich, G. Grampp, and B. Mounho Biosimilars 2.0: Guiding principles for a global patients first standard MAbs 3 2011 318 325
10. L. Tothfalusi, L. Endrenyi, and S. Chow Statistical and regulatory considerations in assessments of interchangeability of biological drug products Eur J Health Econ 15 Suppl 1 2014 S5 S11
11. Biologics Price Competition and Innovation Act. Federal register. 2010; H.R. 3590-686-702. [consultado 8 May 2015]. Disponible en: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/UCM216146.pdf
12. L. Endrenyi, C.H. Chang, S. Chow, and L. Tothfalusi On the interchangeability of biologic drug products Statist Med 32 2013 434 441
13. Sociedad Española de Reumatología. Documento de posicionamiento de la SER sobre fármacos biosimilares [consultado 25 Ene 2015]. Disponible en: http://www.ser.es/actualidad/noticias/documento-de-posicionamiento-de-la-ser-sobre-farmacos-biosimilares/1842
14. F. Argüelles-Arias, M. Barreiro de Acosta, F. Carballo, J. Hinojosa, and T. Tejerina Posición conjunta de la Sociedad Española de Patología Digestiva y de la Sociedad Española de Farmacología sobre el tratamiento con biosimilares en la enfermedad inflamatoria intestinal Rev Esp Enferm Dig 105 2013 37 43
15. Confederación de Asociaciones de Enfermos de Crohn y Colitis Ulcerosa de España. Contra la intercambiabilidad de fármacos biosimilares. [consultado 25 Ene 2015]. Disponible en: http://accuesp.com/news/es/2013/05/30/0001/contra-la-intercambiabilidad-de-farmacos-biosimilares
16. L. Puig Biosimilars in psoriasis 2015: What is next? J Eur Acad Dermatol Venereol 2014 10.1111/jdv.12843 [Epub ahead of print]
17. Q. Tan, Q. Guo, C. Fang, C. Wang, B. Li, H. Wang, and et al. Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein products MAbs 4 2012 761 774
18. V.F. Azevedo, N. Galli, A. Kleinfelder, J. D'Ippolito, and P.C. Urbano Etanercept biosimilars Rheumatol Int 35 2015 197 209